华东医药
(000963)
| 流通市值：714.27亿 | | | 总市值：715.14亿 |
| 流通股本：17.52亿 | | | 总股本：17.54亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 3,711,981,117.29 | 5,276,440,245.36 | 4,739,290,249.11 | 5,650,547,127.07 |
| 衍生金融资产 | - | - | - | 16,488,136.54 |
| 应收票据及应收账款 | 11,558,233,812.68 | 8,436,055,203.47 | 9,959,874,617.5 | 7,975,907,427.49 |
| 其中：应收票据 | - | 10,696,341.24 | - | 11,341,351.13 |
| 应收账款 | 11,558,233,812.68 | 8,425,358,862.23 | 9,959,874,617.5 | 7,964,566,076.36 |
| 应收款项融资 | 988,196,245.72 | 1,677,636,420.09 | 615,997,329.9 | 1,659,103,759.04 |
| 预付款项 | 509,401,242.97 | 400,291,510.71 | 453,619,057.35 | 331,737,711.33 |
| 其他应收款合计 | 571,866,490.76 | 402,870,356.31 | 526,012,334.37 | 411,505,485.2 |
| 应收股利 | 223,608.84 | 223,608.84 | 223,608.84 | 223,608.84 |
| 存货 | 4,993,004,391.03 | 4,776,397,278.01 | 4,906,568,632.85 | 4,379,240,489.45 |
| 其他流动资产 | 74,540,402.52 | 82,099,747.34 | 52,102,427.05 | 81,397,040.52 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 22,407,223,702.97 | 21,051,790,761.29 | 21,253,464,648.13 | 20,505,927,176.64 |
| 非流动资产: | | | | |
| 长期股权投资 | 1,513,925,302.98 | 1,543,646,404.76 | 1,504,680,048.89 | 1,540,257,326.17 |
| 其他权益工具投资 | 711,111,696.58 | 603,232,766.22 | 597,327,085.25 | 566,568,278.72 |
| 投资性房地产 | 11,589,767.25 | 11,842,042.67 | 12,056,372.93 | 12,270,841.77 |
| 固定资产 | 4,333,070,220.62 | 4,422,300,775.01 | 4,151,614,313.81 | 4,158,172,111.39 |
| 在建工程 | 952,469,422.55 | 836,739,481.6 | 956,356,801.65 | 918,366,234.28 |
| 使用权资产 | 141,646,790.18 | 149,504,562.99 | 163,209,658.39 | 157,318,875.96 |
| 无形资产 | 3,786,366,926.5 | 3,644,956,428.71 | 2,548,279,294.67 | 2,486,120,816.95 |
| 开发支出 | 1,120,038,511.44 | 1,033,392,377.69 | 1,220,784,671.74 | 1,149,241,824.64 |
| 商誉 | 2,918,760,393.01 | 2,913,334,523.63 | 2,909,064,173.67 | 2,591,744,585.15 |
| 长期待摊费用 | 20,884,747.76 | 22,601,572.13 | 21,569,252.06 | 19,756,292.05 |
| 递延所得税资产 | 223,505,398.13 | 221,848,889.06 | 232,727,968.46 | 233,149,891.4 |
| 其他非流动资产 | 1,306,566,802.34 | 1,423,855,781.39 | 1,924,119,435.95 | 1,827,889,520.52 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 17,039,935,979.34 | 16,827,255,605.86 | 16,241,789,077.47 | 15,660,856,599 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 39,447,159,682.31 | 37,879,046,367.15 | 37,495,253,725.6 | 36,166,783,775.64 |
| 流动负债: | | | | |
| 短期借款 | 2,453,068,051.27 | 2,312,339,143.21 | 1,833,368,155.46 | 1,405,140,132.05 |
| 应付票据及应付账款 | 7,742,103,457.21 | 7,044,456,734.27 | 7,623,754,972.93 | 6,975,514,379.96 |
| 其中：应付票据 | 2,963,905,693.12 | 2,576,685,923.31 | 2,766,860,378.77 | 2,184,117,028.14 |
| 应付账款 | 4,778,197,764.09 | 4,467,770,810.96 | 4,856,894,594.16 | 4,791,397,351.82 |
| 预收款项 | 2,394,374.93 | 1,115,173 | 1,707,483.62 | 1,732,122.7 |
| 合同负债 | 175,030,504.6 | 173,609,109.58 | 128,171,949.61 | 125,051,134.31 |
| 应付职工薪酬 | 219,912,857.71 | 417,133,101.11 | 208,737,763.77 | 213,405,220.46 |
| 应交税费 | 669,769,811.98 | 645,950,867.22 | 536,518,574.86 | 452,700,174.26 |
| 其他应付款合计 | 2,957,810,000.79 | 2,849,833,595.48 | 3,606,014,657.41 | 3,426,723,106.12 |
| 应付股利 | 125,024,219.6 | 125,024,219.6 | 143,024,219.6 | 146,258,219.6 |
| 一年内到期的非流动负债 | 110,782,003.1 | 330,528,920.89 | 378,428,427.31 | 683,210,855.71 |
| 其他流动负债 | 20,456,908.65 | 19,268,728.25 | 16,262,707.17 | 9,434,101.9 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 14,351,327,970.24 | 13,794,235,373.01 | 14,332,964,692.14 | 13,292,911,227.47 |
| 非流动负债: | | | | |
| 长期借款 | 14,642,806.35 | 14,262,841.05 | 67,979,467.42 | 81,565,510.08 |
| 租赁负债 | 89,138,466.89 | 71,857,938.46 | 88,779,151.93 | 69,083,110.73 |
| 长期应付款 | 23,479,876.74 | 24,715,073.51 | 24,144,309 | 25,507,681.65 |
| 预计负债 | 28,690,397.55 | 28,985,982.19 | 37,294,797 | 37,973,290.55 |
| 递延收益 | 180,766,396.92 | 183,855,718.48 | 147,307,332.45 | 158,889,475.61 |
| 递延所得税负债 | 196,417,169.62 | 197,378,528.33 | 180,093,287.69 | 173,389,997.24 |
| 其他非流动负债 | - | - | 46,192,650 | 46,192,650 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 533,135,114.07 | 521,056,082.02 | 591,790,995.49 | 592,601,715.86 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 14,884,463,084.31 | 14,315,291,455.03 | 14,924,755,687.63 | 13,885,512,943.33 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 1,754,077,048 | 1,754,262,548 | 1,754,262,548 | 1,754,327,548 |
| 资本公积 | 2,549,212,445.78 | 2,550,780,602.69 | 2,487,606,390.48 | 2,484,397,834.82 |
| 减:库存股 | 42,168,791.67 | 46,804,116.67 | 80,458,069.07 | 82,074,369.07 |
| 其他综合收益 | 31,446,768.3 | -50,598,204.17 | -22,665,647.88 | -46,627,046.46 |
| 盈余公积 | 1,395,568,477.98 | 1,395,568,477.98 | 1,277,779,972.18 | 1,277,779,972.18 |
| 未分配利润 | 18,371,550,574.23 | 17,456,842,089.53 | 16,624,852,605.71 | 16,372,490,548.27 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 24,059,686,522.62 | 23,060,051,397.36 | 22,041,377,799.42 | 21,760,294,487.74 |
| 少数股东权益 | 503,010,075.38 | 503,703,514.76 | 529,120,238.55 | 520,976,344.57 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 24,562,696,598 | 23,563,754,912.12 | 22,570,498,037.97 | 22,281,270,832.31 |
| 负债和股东权益合计 | 39,447,159,682.31 | 37,879,046,367.15 | 37,495,253,725.6 | 36,166,783,775.64 |
| 公告日期 | 2025-04-25 | 2025-04-18 | 2024-10-25 | 2024-08-16 |
| 审计意见(境内) | | 标准无保留意见 | | |